ANI Pharmaceuticals, Inc.
ANIP
$82.10
-$0.57-0.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 26.62M | 8.55M | 15.68M | -10.28M | -24.17M |
| Total Depreciation and Amortization | 22.63M | 23.28M | 22.89M | 22.60M | 15.75M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.64M | 7.75M | -4.91M | 8.32M | 12.56M |
| Change in Net Operating Assets | -17.84M | 36.24M | 1.33M | -4.78M | 8.33M |
| Cash from Operations | 44.06M | 75.81M | 34.99M | 15.86M | 12.47M |
| Capital Expenditure | -6.10M | -4.01M | -2.47M | -2.39M | -4.81M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -8.20M | -393.08M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -60.00K | -2.90M | -17.37M | -86.00K | -631.00K |
| Cash from Investing | -6.16M | -6.91M | -19.85M | -10.68M | -398.52M |
| Total Debt Issued | -- | -- | -- | 0.00 | 641.25M |
| Total Debt Repaid | -2.03M | -2.03M | -2.03M | -156.00K | -294.38M |
| Issuance of Common Stock | 9.79M | 1.24M | 2.53M | 1.70M | 1.19M |
| Repurchase of Common Stock | -1.04M | -551.00K | -10.00M | -318.00K | -680.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -344.00K | -407.00K | -406.00K | -406.00K | -406.00K |
| Other Financing Activities | -26.00K | -- | -- | -5.73M | -55.95M |
| Cash from Financing | 6.35M | -1.75M | -9.91M | -4.91M | 291.03M |
| Foreign Exchange rate Adjustments | 576.00K | 841.00K | -297.00K | -395.00K | -75.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.81M | 68.00M | 4.94M | -123.00K | -95.09M |